Unjha Formulations Ltd

Unjha Formulations Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 5 August 2026, reflecting a complex interplay of technical, valuation, financial trend, and quality factors. Despite an attractive valuation and solid long-term returns, recent technical signals and flat quarterly financials have raised concerns among analysts, prompting a reassessment of the stock’s outlook.

Unjha Formulations Ltd., a Gujarat-based pharmaceutical company specialising in Isabgol (Psyllium) formulations, reported a marginal improvement in its Q1 FY27 results, posting a net profit of ₹0.16 crores, a modest recovery from the loss-making Q4 FY26. However, the company's performance remains marred by persistent volatility and declining year-on-year metrics, raising questions about its operational stability and growth trajectory.

Unjha Formulations Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, signalling a positive change in price attractiveness amid a challenging pharmaceuticals sector. This micro-cap stock’s recent performance and valuation metrics merit close attention from investors seeking value in the Pharmaceuticals & Biotechnology space.

With a decisive surge to Rs 29.5 on 30 Jul 2026, Unjha Formulations Ltd has reached a fresh 52-week high, marking a significant milestone in its price momentum. This rally comes after a sustained four-day gain, delivering a 23.9% return in that period and outpacing its sector by over 7% today alone.

With a decisive surge to Rs 28.76 on 29 Jul 2026, Unjha Formulations Ltd has reached a fresh 52-week high, propelled by a confluence of bullish technical indicators and sustained price momentum over recent sessions.

Unjha Formulations Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 8 July 2026, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The pharmaceutical micro-cap’s recent price action and technical signals have improved, prompting a reassessment of its market stance, even as financial trends remain subdued and valuation metrics present a mixed picture.

A sharp decline of 12.36% today dragged Unjha Formulations Ltd to a fresh 52-week low of Rs 17.52, marking a significant setback after four consecutive days of gains. This drop comes amid a broader market rally, highlighting a stark divergence in the stock’s performance.